Abstract:Chimeric antigen receptor (CAR)-T cell therapy has demonstrated poor efficacy for solid tumors. The low number and poor functional persistence of CAR-T cells in tumors are the main limiting factors. Here a Chemokine-based Injectable platform for enhancing adoptive T cells' Efficacy (CITE) is presented. CITE consists of peritumorally-injected immunogel co-loading chemotactic CXCL9 particles with PD-1 antibody (aPD1) and intravenously-infused tumor-penetrating peptide iRGD. Immunogel formed drug depots and allowed sustained release of cargo peritumorally while iRGD facilitated tumor infiltration of gel-released drugs, thus remarkably increasing the amount of CXCL9 and aPD1 in the tumor. CITE induced an effective chemotactic gradient to promote the tumor-specific migration of CAR-T cells and boosted the function of infiltrated T cells by blocking immunosuppression via a two-in-one approach. Consequently, CITE yielded a 218-fold increase in the intratumoral number of transferred T cells and substantially improved the efficacies of transferred T cell receptor (TCR)-T cells and CAR-T cells in multiple syngeneic tumor models, including immunologically "cold" tumors, in immunocompetent mice. More importantly, CITE enhanced systemic antitumor immunity and elicited immune memory, enabling CITE to treat multimodal, metastatic, and recurrent tumors. CITE is broadly applicable to adoptive cell therapies involving CAR-T or TCR-T cells. The CITE (Chemokine-based Injectable platform for boosting adoptive T cells' Efficacy) system promotes the tumor-specific migration of CAR-T cells and boosts the function of infiltrated T cells via a two-in-one approach, thus substantially improving the efficacies of CAR-T cells to solid tumors. CITE also enhances systemic antitumor immunity and elicits immune memory, enabling CITE to treat multimodal, metastatic and recurrent tumors. image

Scattered Seeding of CAR T Cells in Solid Tumors Augments Anticancer Efficacy

Injectable Porous Microchips with Oxygen Reservoirs and an Immune-Niche Enhance the Efficacy of CAR T Cell Therapy in Solid Tumors

Elevating the potential of CAR-T cell therapy in solid tumors: exploiting biomaterials-based delivery techniques

CAR-T in solid tumors: Blazing a new trail through the brambles

Lymph node-biomimetic scaffold boosts CAR-T therapy against solid tumor

Innovative Strategies to Advance CAR T Cell Therapy for Solid Tumors.

Delivery Techniques for Enhancing CAR T Cell Therapy Against Solid Tumors

Chimeric Antigen Receptor T Cells Applied to Solid Tumors

Programming CAR T cells to enhance anti-tumor efficacy through remodeling of the immune system

CAR T Cell Membrane Camouflaged Nanocatalyst Augments CAR T Cell Therapy Efficacy Against Solid Tumor.

CXCL9-modified CAR T cells improve immune cell infiltration and antitumor efficacy

A new era of cancer immunotherapy: combining revolutionary technologies for enhanced CAR-M therapy

Chemokine‐Based Injectable Navigation System for Enhancing CAR‐T Cell Therapy Against Solid Tumors

Improving the ability of CAR-T cells to hit solid tumors: Challenges and strategies

Rationally designed approaches to augment CAR-T therapy for solid tumor treatment

Revolutionizing cancer immunotherapy in solid tumor: CAR engineering and single-cell sequencing insights

CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment

Advances in promoting chimeric antigen receptor T cell trafficking and infiltration of solid tumors

Abstract 2838: Antigen-independent Expansion Enhances Efficacy of CAR-T Cells Against Solid Tumor

A long way to the battlefront: CAR T cell therapy against solid cancers.

CAR T cell infiltration and cytotoxic killing within the core of 3D breast cancer spheroids under control of antigen sensing in microwell arrays